Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 18/20 | 0.69 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.65 |
| ▸ | KDM3A | Q9Y4C1 | 5/20 | 0.65 |
| ▸ | KDM5A | P29375 | 4/20 | 0.65 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.65 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.61 |
| ▸ | KDM6B | O15054 | 3/20 | 0.61 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25279052 | 0.86 | KMO (0.61) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL2407260 | 0.80 | KDM4C (0.72) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL31301524 | 0.78 | KMO (0.71) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL70700 | 0.76 | KDM4C (0.78) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL29407015 | 0.76 | KDM4C (0.78) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL2406313 | 0.75 | RXRA (0.58) | KMO | |
| SCHEMBL14976723 | 0.74 | KDM4C (0.59) | KDM4CKDM5BKDM3AKDM2AKDM6B | |
| SCHEMBL2406744 | 0.74 | KDM4C (0.46) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL25221788 | 0.74 | KDM4C (0.75) | KDM4CKDM5BKDM3AKDM5AKDM4D | |
| SCHEMBL25220048 | 0.74 | KDM4C (0.75) | KDM4CKDM5BKDM3AKDM5AKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | claimed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | claimed |
| CN-1444477-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | claimed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | claimed |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2015-04-02 | — | — | US | disclosed |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC | 2013-03-28 | — | — | US | disclosed |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | GLAXOSMITHKLINE LLC. | 2011-09-01 | — | — | US | disclosed |
| US-7790704-B2 | Thrombopoietin mimetics | GlaxoSmithKline, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7674887-B2 | Thrombopoietin mimetics | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| US-7648971-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1889838-B1 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED | 2007-08-02 | — | — | US | disclosed |
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION | 2007-06-07 | — | — | US | disclosed |
| US-7160870-B2 | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040019190-A1 | Thrombopoietin mimetics | NOVARTIS AG (CH) | 2004-01-29 | — | — | US | disclosed |
| EP-1294378-A4 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| CN-1444477-A | Thrombopoietin mimetics | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | CN | disclosed |
| EP-1294378-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001089457-A2 | THROMBOPOIETIN MIMETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129338-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM4C 3347/4885KDM5B 1609/4885KDM3A 3333/4885 |
| US-20070179192-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM4C 3347/4885KDM5B 1609/4885KDM3A 3333/4885 |
| US-20150093356-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM4C 3347/4885KDM5B 1609/4885KDM3A 3333/4885 |
| US-20110212054-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM4C 3347/4885KDM5B 1609/4885KDM3A 3333/4885 |
| US-20130078213-A1 | THROMBOPOIETIN MIMETICS | MPL, THPO, TEK | KDM4C 3347/4885KDM5B 1609/4885KDM3A 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.